The researchers concluded: The GLP-1 analogue semaglutide decreased alcohol intake across different drinking models and species and modulated central GABA neurotransmission, providing support for clinical testing of semaglutide as a potentially novel pharmacotherapy for AUD. Dr Leggio told CNN drugs like semaglutide may influence interest in things like alcohol because they have an effect not just in the gut, but in the brain
Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal
This signalling cascade can enhance mitochondrial function, improve cellular energy production, and activate anti-apoptotic (cell survival) pathways
This encapsulation property of liposomes makes them an effective drug delivery system that can improve drug stability and bioavailability while reducing toxic side effects and enabling targeted delivery
Research shows that social support leads to better treatment adherence, improved mood, and longer-term health outcomes
The following symptoms warrant prompt medical attention and patients should contact their GP or seek urgent care if they experience: Severe or persistent abdominal pain , which may indicate pancreatitis a recognised risk with GLP-1-containing therapies [13] Jaundice, right upper quadrant pain, or fever , which may suggest gallbladder disease Signs of dehydration or reduced kidney function , such as dizziness, markedly reduced urine output, or confusion, particularly if vomiting or diarrhoea is prolonged Visual changes , particularly in individuals with pre-existing diabetic retinopathy Patients taking retatrutide alongside insulin or a sulfonylurea should be aware of an increased risk of hypoglycaemia (low blood sugar)
